Human achaete scute homolog 2 (HASH2) and its murine ortholog MASH2 are potential targets for colorectal cancer immunotherapy. We assessed immunogenicity and antitumor potential of recombinant MASH2 protein combined with AS15 immunostimulant (recMASH2+ AS15) in CB6F1 ; no significant difference). recMASH2+AS15 induced MASH2-specific antibody and CD4+ responses in both mouse models. recMASH2+AS15 partially protected mice against MASH2-expressing tumors and reduced spontaneous colorectal adenomas in Apc +/Min-FCCC mice, indicating that MASH2/HASH2 antigens are targets for colorectal cancer immunotherapy.
Introduction
Colorectal cancer (CRC) is one of the most common cancers of the Western world and a leading cause of cancer-related mortality [1] [2] [3] . Unfortunately, 30%-40% of CRC patients have a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 local, regionally advanced or metastatic disease that cannot be cured by surgery [4] . Despite recent progress in diagnosis and treatment, the prognosis of patients with advanced CRC remains poor [5] .
Genetic and environmental factors contribute to the risk of developing CRC [6] [7] [8] [9] [10] [11] [12] . Primary prevention efforts continue to focus on either reducing factors that confer CRC risk or intervening with chemopreventive agents. Populations at highest risk for CRC (i.e. individuals >age 50, with a family history of CRC or inflammatory bowel disease) continue to be the target of screening programs that utilize various molecular techniques to detect malignancy at an early stage [6, 8, 10, [13] [14] [15] . While several agents have been identified that can prevent or suppress the progression of precursor lesions, adverse effects occur. The chemopreventive activity of cyclooxygenase-2 inhibitors and aspirin is accompanied by an increased risk of cardiovascular events, and gastrointestinal and intracranial bleeding, respectively [16] [17] [18] [19] [20] [21] . Thus, the search for safe and cost-effective drugs for the prevention and treatment of CRC continues.
Emerging data highlight the importance of the host immune system in controlling the growth and evolution of CRC. A complex interaction between tumor cells and the local immune response results in a balance between tumor-promoting and -controlling effects, and a close interaction of the innate and adaptive immune systems [4, 22] . In CRC patients, tumor-infiltrating immune cells were independent prognostic factors of overall and progression-free survival. Increased infiltration of CRC tumors by cytotoxic memory T-lymphocytes (i.e. CD8+ or CD45RO+) was highly correlated with reduced risk of recurrence and improved survival [23] [24] [25] [26] . These findings suggest that mobilizing the immune system of CRC patients could lead to clinical benefit.
Various immunotherapeutic approaches have been developed to harness the immune system in combating CRC. However, despite promising results with immune checkpoint inhibitors, viral vector-based immunotherapies, dendritic cell or peptide vaccines, or irradiated autologous tumor cells, there are no approved antigen-specific cancer immunotherapies for the treatment of CRC [27, 28] .
The canonical Wnt signaling pathway is involved in the renewal and proliferation of stem cells, as well as cell differentiation [29, 30] . In the absence of Wnt signaling, the adenomatous polyposis coli (APC) protein forms a complex with the GSK3β, Axin, Dsh and β-catenin proteins, leading to degradation of β-catenin. Upon stimulation of Wnt signaling, β-catenin accumulates in the cytoplasm and subsequently translocates to the nucleus where it activates the transcription of numerous oncogenes. Likewise, mutational inactivation of the Apc gene results in constitutive activation of Wnt signaling, continuous expression of oncogenes, and ultimately tumorigenesis [30, 31] . Apc mutations are present in over 80% of sporadic CRCs in humans [30] [31] [32] .
The that spontaneously develops colorectal adenomas at a high multiplicity and high incidence (81.8%), as compared to the conventional Min mouse strain, provides a relevant model for studying colorectal neoplasia; in addition, the extended life-span of the Apc +/Min-FCCC mice provides a sufficient window of opportunity for therapeutic intervention [33] . Human achaete scute homolog 2 (Hash2 or achaete scute-like 2) and its murine ortholog Mash2 encode basic helix-loop-helix transcription factors that are essential for differentiation of the mammalian trophoblast lineage [34] ; HASH2 and MASH2 share 78.5% amino acid sequence homology and act as master regulators of intestinal stem cell identity [35] [36] [37] . Wntmediated regulation of Hash2 expression may explain why the majority of human CRCs are 
Materials and methods

Animal source
Study design
Transplanted TC1-MASH2 tumor model. Female CB6F1 mice (C57BL/6 x BALB/c, 6-8 weeks of age) were maintained under pathogen-free conditions. Mice received 4 intramuscular (IM) injections (50 μl) of either 10 μg recMASH2+AS15 or AS15 alone at 2-week intervals; AS15 was used at 1/10 th of the human dose (Fig 1) . Two weeks after the last immunization, mice were challenged with a subcutaneous injection of 500,000 TC1-MASH2 tumor cells (200 μl in the flank) expressing the MASH2 protein (see S1 Appendix). Individual tumor growth (product of the two largest diameters) was recorded 3 times a week, starting 7 days after challenge. Clinical examination was performed on a daily basis. Mice were euthanized when the tumor size reached 289 mm 2 or at 70 days post-challenge, using 20% sodium pentobarbital solution (100 μl/mouse). All treatments were administered in the semi-tendinous muscle of the hind leg. In Apc +/Min-FCCC mice, AS15 was used at 1/20 th of the human dose. All mice were monitored daily for swelling/redness at the injection site, dehydration, and cachexia. Body weights were measured at the time of injection and for 4 subsequent days. Mice exhibiting >20% weight loss were euthanized immediately by inhalation of carbon dioxide and the organs collected for analysis. All Apc +/Min-FCCC mice were euthanized at study week 22 and necropsied.
For the Prophylactic Studies, Apc +/Min-FCCC mice confirmed to be tumor-free by colonoscopy at 4 weeks of age were randomized one week later to receive 9 IM injections (50 μl) of either phosphate-buffered saline (PBS) or 10 μg recMASH2+AS15 (Study 1) or PBS, AS15 or 10 μg recMASH2+AS15 (Study 2) every other week (Fig 1) . In the Immunotherapy Study, Apc +/Min-FCCC mice confirmed by colonoscopy to have tumors at 7 weeks of age were randomized to receive 9 IM injections of PBS, AS15 or recMASH2+AS15. The first 4 injections were administered weekly, starting at 8 weeks of age, and the last 5 injections were given every 2 weeks (Fig 1) .
Histopathology
The following organs were collected from all animals for evaluation: cerebellum, trachea, salivary gland, stomach, esophagus, bladder, colon, small intestine, testis, prostate, thymus, spleen, pancreas, kidney, liver, lung, brain, skin, and heart. After formalin fixation, paraffin sections (7-10 μm thick) were stained with hematoxylin-eosin. Masson's trichrome method, Cresyl violet or the Klüver-Barrera method was used to stain the brain samples. At sacrifice, the entire colon and small intestine of Apc +/Min-FCCC mice were excised and the number of gross colon and small intestinal tumors was counted. All tissues were fixed in 10% normal buffered formalin overnight and embedded in paraffin. Following fixation, the small intestine and colon were cut into proximal, mid and distal segments and either "jelly rolled" or cut at 2-mm intervals for paraffin embedding, respectively. Hematoxylin-eosin-stained sections were pathologically examined in a blinded manner. Adenomas were classified as polypoid, nonpolypoid, indeterminate or microadenomas (Fig  2) . Any adenoma exhibiting an elevated growth pattern, grossly or microscopically, was considered polypoid. Nonpolypoid (flat) lesions displayed a height less than twice that of the adjacent nonneoplastic mucosa. Indeterminate adenomas did not fit into the criteria of either polypoid or flat. Microadenomas (1-4 crypts) were undetectable upon gross examination. The total number of adenomas per mouse was determined by summing the polypoid, flat, indeterminate and microadenomas. Small intestinal adenomas were identified grossly and histopathologically confirmed in cross sections of jelly rolls.
Immunological analyses
The MASH2-specific antibody response was evaluated in sera from each mouse using an enzyme-linked immunosorbent assay. Sera were analyzed in all mice 14 days after the 4th injection (Fig 1) and again in Apc +/Min-FCCC mice after the 9th injection. Antibody titers were determined with a mouse immunoglobulin G (IgG) standard curve using a specific capture IgG antibody. The MASH2-specific T-cell response was evaluated by intracellular cytokine staining and flow cytometry to assess the percentage of CD4+ or CD8+ T-cells producing interferongamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) in splenocytes of individual mice (see S1 Appendix). Splenocytes were isolated 14 days after the 4 th (CB6F1 and Apc +/Min-FCCC mice) and 9 th (Apc +/Min-FCCC mice only) injection (Fig 1) and re-stimulated with a MASH2
peptide matrix (pools of 15mer peptides overlapping by 11 amino acids covering the entire MASH2 sequence) or culture media (see S1 Appendix).
Statistical analyses
All analyses were performed using SAS version 9.2. Tumor size in CB6F1 mice. Mean size of the tumor, calculated with a 95% confidence interval (CI), was compared between two groups using an analysis of variance model. When a mouse died prior to the end of the study (70 days post-challenge), the last measure of its tumor size was used to calculate the mean tumor size at the end of the study.
Tumor analyses in Apc +/Min-FCCC mice. Polypoid, flat, microadenoma, and indeterminate adenomas were considered for analysis. The sum of the number of tumors in each mouse was computed. Microadenomas were further analyzed with respect to their location (proximal, mid, and distal colon). The number of tumors by type was modeled in each study using Poisson distribution. The overdispersion parameter was estimated using the deviance method and the rate of event was reported over 22 weeks (length of each study). The same approach was used to estimate the event rate in the PBS and recMASH2+AS15 groups during Prophylactic Studies 1 and 2, with study as a factor. The differences between two groups were considered significant for p-values <0.05; no pre-specified cut-off for significance was defined in the protocol. Time-to-euthanasia or death. Euthanasia or death that did not occur during anesthesia was considered a 'treatment failure'. Mice that died under anesthesia were censored at the time of death. Time-to-treatment failure was compared between groups using a Cox-proportional hazard model that included study as a factor for comparisons between the recMASH2+AS15 and control (PBS or AS15) groups. Kaplan-Meier estimates of survival are provided. Table A and Table B in S1 Appendix), the immunodominant MASH2 peptides were peptide 41 (RSAVEYIRALQRLLA, 100% conserved in HASH2) and peptide 25 (PELLRCSRR RRSGAT); these peptides also contain HASH2 immunodominant CD4 epitopes identified in CB6F1 mice injected with recHASH2+AS15 (unpublished GSK data). No MASH2-specific CD8+ T-cells were observed. The antitumor activity of recMASH2+AS15 was assessed by challenging mice (15/group) with TC1-MASH2 cells and monitoring tumor growth for 70 days. Only 1 of 15 mice (7%) receiving AS15 alone survived until the end of the study and was tumor-free. In contrast, 10 of recMASH2+AS15 immunotherapy protects mice against colorectal cancer 15 mice (67%) injected with recMASH2+AS15 completed the entire study (p = 0.001), of which 7 (70%) were tumor-free (Fig 3A) . The mean size of tumors in mice treated with recMASH2+AS15 was smaller than that of the AS15 group (Fig 3B) . Significant differences in tumor size were observed starting on day 13 of the challenge (p<0.001) and remained significant until the end of study (104 mm 2 for recMASH2+AS15 vs. 197 mm 2 for AS15, p = 0.009).
Ethics statement
recMASH2+AS15 induces immune responses and inhibits the formation of colon and small intestinal tumors in Apc +/Min-FCCC mice
To evaluate the capacity of repeat immunizations with recMASH2+AS15 to inhibit sporadic colorectal adenomas, two independent Prophylactic Studies were conducted. In both studies, male Apc +/Min-FCCC mice were tumor-free at baseline. In Study 1, mice received recMASH2 +AS15 (n = 20), or PBS as control (n = 25). In Study 2, mice received recMASH2+AS15 (n = 53), PBS (n = 51) or AS15 alone (n = 57). After 4 injections, a strong MASH2-specific IgG antibody response was observed in Apc +/Min-FCCC mice immunized with recMASH2+AS15 (Study 1: GMT 8.9 x 10 5 ng/ml; Study 2: 7.9 x 10 5 ng/ml), which remained high following 9
injections (Study 1: 8.5 x 10 5 ng/ml; Study 2: 1.1 x 10 6 ng/ml). No response was measured in mice treated with PBS or AS15 alone. After 9 injections of recMASH2+AS15, a strong induction of MASH2-specific CD4+ T-cells producing TNF-α and IFN-γ was observed (Study 1: 9.1%; Study 2: 11.4%); no MASH2-specific CD8+ T-cells were observed. Cytokine-producing CD4+ T-cells were not induced in mice injected with either PBS or AS15 alone. In Study 1, the total number of colon adenomas was significantly lower in the recMASH2 +AS15 group versus the PBS group (mean 1. (Fig 4A) . In Study 2, the antitumor activity of recMASH2+AS15 was restricted to colon microadenomas, with the mean number in recMASH2+AS15 mice significantly lower than those administered PBS (0. (Fig 4B) . The mean number of flat and indeterminate adenomas did not differ significantly across the treatment groups in either Study 1 or 2 (Fig 4A and 4B) .
The same trend was observed when data from all mice in both studies were pooled, with a significantly lower number of total microadenomas in the recMASH2+AS15 group vs. PBS (0.4 vs. 1.2, p<0.001). With respect to location, the largest response to recMASH2+AS15 treatment in Study 2 was observed among distal microadenomas (mean 0. Fig 5) .
The ability of recMASH2+AS15 to inhibit the formation of colorectal tumors was also evident from an increased number of tumor-free mice at the end of the study. The majority (74%) of the gross colon adenomas identified at necropsy were located within the region accessible to the endoscope. In Study 1, 4/19 (21%) mice in the recMASH2+AS15 group were tumor-free at necropsy, as compared to 2/20 (10%) of PBS-injected controls. 
Evaluation of safety
Because low levels of MASH2 mRNA are expressed in select normal murine tissues [34, 40, 41] , potential treatment-induced toxicity was assessed. Similar to C57Bl/6 control mice, very low levels of MASH2 mRNA were detected in the normal colon and small intestine of Apc +/Min-FCCC mice. However, MASH2 mRNA was overexpressed in spontaneous adenomas of the colon and small intestine (unpublished GSK data). No histological abnormalities indicative of organ toxicity were observed in the bladder, brain, cerebellum, esophagus, heart, 
Discussion and conclusions
The results of our studies indicate the capacity of the recombinant MASH2 protein (a self-antigen for mice), formulated with AS15 immunostimulant, to induce humoral and cellular immune responses. recMASH2+AS15 significantly decreased the growth of MASH2-expressing Although transplantable tumors are easy to handle in a laboratory setting, they grow fast and may not fully mimic the slow tumor growth in human patients. Therefore, we have also evaluated the impact of recMASH2+AS15 immunotherapy on the spontaneous development of intestinal tumors in Apc +/Min-FCCC mice, an animal model, which more closely reflects the way CRC develops in its natural site, and in which the results are expected to be more predictive of therapeutic outcome in future human trials. Experiments were designed to mimic either prophylaxis in patients at high risk for CRC or its recurrence, or immunotherapy in patients with existing colon tumors. In both experiments, recMASH2+AS15 reduced the formation of colorectal microadenomas. Injection of mice with recMASH2+AS15 resulted in strong induction of MASH2-specific antibodies and cytokine-producing CD4+ T-cells. No CD8+ T-cell response was detected, consistent with previous data from mice injected with AS15 combined with another recombinant protein coding for another tumor antigen, MAGE-A3 [42] . As demonstrated in CD8+ Tcell-depleted mice or perforin-KO mice, CD8+ T-cells did not account for the antitumor response observed in a MAGE-A3-transfected tumor model and CD4+ T-cells were the critical effector. Since antitumor activity was observed in the absence of CD8+ T-cell responses in the present study, CD4+ T-cells seem to be the critical effector in CRC as well. MASH2 is an intracellular protein; thus, antibodies are not expected to play a direct role in tumor cell killing through antibody-dependent cellular cytotoxicity. However, immune complexes can be taken up by antigen presenting cells via their Fcγ receptor and cross-presented to T-cells, thereby indirectly contributing to tumor rejection [43, 44] . Because cytotoxic CD8+ T-cells are often considered the primary cells responsible for tumor elimination in humans [23, 26, 45, 46] , the addition of an approach to induce CD8+ T-cell response could lead to improved HASH2 efficacy in humans. A more potent immunostimulant, including recombinant adenoviruses or RNA vaccines, could be a good candidate for this purpose [28] . However, induction of CD4 + T-cell responses would be a prerequisite, as they accompany the observed antitumor activity of MASH2 and help induce and maintain CD8+ T-cell responses [47] [48] [49] .
recMASH2 coupled with the AS15 immunostimulant was immunogenic and increased the disease-free survival of Apc +/Min-FCCC mice. However, this strategy alone may be insufficient to provide clinical benefit to cancer patients, requiring combination therapy. One option would be use in combination with cyclophosphamide to break regulatory T-cell-induced tolerance to immunotherapy [50] . Monoclonal antibodies that block immune checkpoints are extremely efficacious in inducing clinical responses in metastatic melanoma and other solid tumors [51, 52] . Such treatment used in combination with antigen-specific immunotherapy may help sustain the immune response and improve clinical benefit. Viral vector approaches, as well as standard chemotherapy or radiotherapy, could also be considered [28] . The concept of HASH2-based immunotherapy for CRC is based on several observations. First, expression of HASH2 in the non-neoplastic intestine is restricted to cells at the base of the crypt, where the protein plays a critical role in controlling stem cell fate [35] . Transgenic expression of HASH2 in the intestinal epithelium leads to crypt hyperplasia, while induced deletion in the adult small intestine causes rapid disappearance of Lgr5-positive progenitors [53] . Second, HASH2 is overexpressed in the majority (up to 71%) of human CRC, with levels elevated 15-fold [35, 37, 38, 53] . By immunohistochemistry using a specific anti-HASH2 monoclonal antibody, we also confirmed the overexpression of HASH2 protein in human colorectal tumors and metastases, compared to adjacent normal tissues (unpublished GSK data). Third, and most importantly, β-catenin-mediated TCF signaling, the target of HASH2, is one of the earliest aberrations in colorectal carcinogenesis. Inhibition of this "gatekeeping" recMASH2+AS15 immunotherapy protects mice against colorectal cancer oncogenic event is consistent with the ability of recMASH2+AS15 to dramatically decrease the multiplicity of microadenomas following prophylactic and immunotherapeutic treatments. In humans, microadenomas are the earliest neoplastic colon lesions that are detected histologically, precursors of "classic" adenomas. Lastly, deregulation of the Wnt pathway leading to methylation of HASH2 is a prognostic factor for CRC recurrence after therapy [54] . Methylation and overexpression of HASH2 has been correlated with poor prognosis and resistance to chemotherapy in gastric cancer [55] . Together, these data highlight the homology between HASH2 and MASH2, and indicate that HASH2 represents a promising target for early immunopreventive intervention in colon carcinogenesis.
Although the HASH2 antigen and its ortholog MASH2 are not only localized to CRC cells [35, 37, 56] , and also present in Lgr5-positive colon progenitors [53, 57] , no safety concerns were identified in this study. Transitory expression of HASH2 or MASH2 mRNA and protein in normal tissues, upon Wnt activation, may explain the absence of adverse events after vaccination with recMASH2+AS15. As CD8+ T-cell responses were not induced, a more potent immunostimulant could be considered in the future, providing an acceptable safety profile can be obtained.
In conclusion, the results of the present study demonstrate that MASH2 and, by extrapolation, HASH2 could be viable targets for immunotherapy of CRC. 
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